Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Dicabba-analogues of octreotide

A compound and chiral carbon technology, applied in the field of analog derivatives of octreotide, can solve problems such as short half-life and clinical use restrictions of somatostatin

Inactive Publication Date: 2011-06-08
ADVANCED ACCELERATOR APPLICATIONS SA
View PDF1 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0008] However, the clinical use of somatostatin is limited due to many disadvantages such as its short half-life in blood (<3 minutes)

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Dicabba-analogues of octreotide
  • Dicabba-analogues of octreotide
  • Dicabba-analogues of octreotide

Examples

Experimental program
Comparison scheme
Effect test

example 1

[0076] Linear heptapeptide Fmoc-Hag 3 (Allyl amino acid)-1-Nal 7 -D-Trp 8 -Lys 9 -Thr 10 -Hag 14 -Thr(ol) 15 Synthesis

[0077] Peptides were prepared in Teflon reactors with porous polystyrene membranes using the Fmoc-SPPS method on pre-swelled H-L-Thr(tBu)-ol-2-chlorotriphenyl resin.

[0078] Coupling steps were performed by adding 2 equivalents of protected amino acid, activated by HATU and 4 equivalents of NMMDMF solution, followed by stirring for 45 minutes for each coupling and monitored by qualitative tests using ninhydrin (Kaiser test).

[0079] Once the synthesis of the linear peptide was complete, microlysis was performed on 5 mg of resin. This resin uses TFA / H 2 Treated with O / 1,2-ethanedithiol (EDT) / phenol (94:2:2:2; 3h) and filtered, the solution was concentrated under reduced pressure and washed with Et 2O precipitated peptides, centrifuged, dissolved in water and lyophilized. Analysis of Fmoc-protected crude peptides by RP-HPLC [Phenomenex Jupiter C18 ...

example 2

[0082] Synthesis of cyclic unsaturated peptides of structural formula (1), wherein -Λ is H, R=benzyl, R 1 is a chemical bond, CH 2 is the D configuration, CH 3 It is L configuration, X=1-Nal, Y=D-Trp, W=Lys, Z=Thr, R 2 =-NHThr(ol)

[0083] The heptapeptide on resin was re-swelled in anhydrous DCM for 2 hours. The reactor was heated to 45 °C and a solution of the second generation Grubbs catalyst, [(L)(L')X 2 Ru=CHR wherein L is a phosphine ligand, L' is a heterocyclic carbene (1,3-bis(2,4,6-trimethylphenyl)-imidazole-2-ylidene) (1,3-dimesityl-imidazol -2-ylidene), X is a Cl atom and R is a phenyl] (0.5 molar equivalent), and the suspension was stirred for 24 hours. The resin was washed with DCM, DMF and MeOH, followed by swelling with DMF. Fmoc-Hag was deprotected with 20% piperidine, and the cyclic peptide coupled to Fmoc-D-Phe was as described previously. This cyclic peptide was deprotected and isolated from the resin as previously described. with Et 2 O concentrate...

example 3

[0086] Synthesis of the unsaturated cyclic peptide of structural formula (1), wherein-Λ is a chelating group DOTA, R=benzyl, R 1 is a chemical bond, CH 2 is the D configuration, CH 3 It is L configuration, X=1-Nal, Y=D-Trp, W=Lys, Z=Thr, R 2 =-NHThr(ol)

[0087] As described in Example 2, the Fmoc-D-Phe of formula I bonded to the resin 2 The deprotection of the peptide was carried out with 20% piperidine; then 2 molar equivalents of DOTA-tri-(t-Bu) ester in DMF, 2 molar equivalents of HATU in DMF and then 4 molar equivalents of NMM were added to in the resin. The equivalent is calculated based on a resin substitution rate of 0.5 mmol / g. The DOTA-conjugated peptide was separated from the resin after the resin was washed for 45 minutes. The tri-(t-Bu)DOTA-protecting group was isolated together with the peptide. The crude peptide was dissolved in water and lyophilized, then purified by RP-HPLC (20%-60% of B in 20 minutes; yield: 29%).

[0088] ESI-MS: found [M+H] + 1417....

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

Analogues of octreotide, their preparation and use are described.

Description

technical field [0001] The present invention relates to analog derivatives of octreotide. Background technique [0002] Somatostatin-14 (SRIF-14) is a cyclic tetradetrapeptide (formula 1) containing a disulfide bridge between two cysteine ​​residues; [0003] [0004] Formula 1: SRIF-14 [0005] SRIF-14 is an important regulator of endocrine and exocrine, and inhibits the release of various other hormones such as glucagon, growth hormone (GH), insulin, gastrin, and others. [0006] Furthermore, based on its distribution in various regions of the brain and spinal cord, somatostatin is thought to play a role in nerve transmission. [0007] According to their structure, phylogenetic and pharmacological properties, SRIF receptors can be divided into two main types: SRIF receptors including sst2, sst3, sst5 1 and SRIF including receptors sst1 and sst4 2 . [0008] However, the clinical use of somatostatin is limited due to many disadvantages such as its short half-life in...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K51/08A61K31/38C07K14/655A61P35/00A61P19/02A61P19/08
CPCC07K14/6555A61K38/00A61K31/38A61K51/088A61P19/02A61P19/08A61P29/00A61P35/00
Inventor 毛罗·金南内施德博拉·达多纳亚历山德拉·迪查尼
Owner ADVANCED ACCELERATOR APPLICATIONS SA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com